ReviewCardiovascular diabetology2022
Diabetes and restenosis.
Review in Cardiovascular diabetology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 5 syntheses or guidelines pooled it, 146 citations in OpenAlex.
- The persisting challenge of recurrent in-stent restenosis: a systematic review and meta-analysis of prevalence and prognostic risk factors.BMC cardiovascular disorders · 2026Pooled it
- Does diabetes affect the incidence of non-target lesion revascularization? A meta-analysis of data from randomized controlled trials.BMC endocrine disorders · 2026Pooled it
- Pooled it
- Risk Factors and Incidence for In-Stent Restenosis with Drug-Eluting Stent: A Systematic Review and Meta-Analysis.Reviews in cardiovascular medicine · 2024Pooled it
- Association between diabetes mellitus and primary restenosis following endovascular treatment: a comprehensive meta-analysis of randomized controlled trials.Cardiovascular diabetology · 2024Pooled it
- Effects of exenatide on coronary stent's endothelialization in subjects with type 2 diabetes: a randomized controlled trial. The Rebuild study.Cardiovascular diabetology · 2023Trial
- Analysis of the incidence and influencing factors associated with binary restenosis of target lesions after drug-coated balloon angioplasty for patients with in-stent restenosis.BMC cardiovascular disorders · 2022Trial
- Contralateral-controlled thigh muscle biomarkers on CT angiography for prediction of 1-year restenosis after endovascular therapy for unilateral peripheral artery disease.Insights into imaging · 2026Article
- Predictive value of remnant cholesterol for in-stent restenosis after drug-eluting stent implantation.Medicine · 2026Article
- Association between systemic immune-inflammation index and systemic inflammation response index and in-stent restenosis in patients with hypertension complicated by coronary heart disease.BMC cardiovascular disorders · 2026Article
- Prognostic impact of metformin in diabetic patients undergoing a percutaneous coronary intervention (PCI): protective effect is modified by procedural complexity.Cardiovascular diabetology · 2026 · on this mapObservational
- Coptis chinensis extracellular vesicles loaded with CA1-siRNA promote endothelial repair and stent restenosis therapy by regulating the PADI2 and NF-κB pathway.Journal of nanobiotechnology · 2026Article
- Optimal Medical Therapy Targeting Metabolic Status for Secondary Prevention in Patients Undergoing Percutaneous Coronary Intervention.Journal of clinical medicine · 2026Review
- Role and mechanisms of vascular smooth muscle cell phenotypic transition in diabetic macrovascular complications.Biological research · 2026Review
- The impact of metabolic syndrome and triglyceride-glucose index on the risk of in-stent restenosis after percutaneous coronary intervention: a retrospective study.Frontiers in cardiovascular medicine · 2026Article
- The association between glycated hemoglobin levels and in-stent restenosis following percutaneous coronary intervention in coronary artery disease patients.Frontiers in endocrinology · 2026Article
- Gingerenone A attenuates diabetic vascular remodeling through AMPK/mTOR/S6K1 signaling.Frontiers in pharmacology · 2026Article
- Determinants of time to severe in-stent restenosis in patients with diabetes mellitus after drug-eluting coronary stenting.Diabetology & metabolic syndrome · 2025Article
- Role of Polymer-Free Drug-Eluting Stents in Insulin-Dependent Diabetic Patients Undergoing Percutaneous Coronary Intervention: An Observational Study.Journal of personalized medicine · 2025Article
- Per- and Polyfluoroalkyl Substances, Serum Lipidome, and Clinical Outcomes after Percutaneous Coronary Intervention in Type 2 Diabetic Patients: A Prospective Nested Case-control Study.Journal of atherosclerosis and thrombosis · 2025Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 2 countries.
Funding
Abstract
Restenosis, defined as the re-narrowing of an arterial lumen after revascularization, represents an increasingly important issue in clinical practice. Indeed, as the number of stent placements has risen to an estimate that exceeds 3 million annually worldwide, revascularization procedures have become much more common. Several investigators have demonstrated that vessels in patients with diabetes mellitus have an increased risk restenosis. Here we present a systematic overview of the effects of diabetes on in-stent restenosis. Current classification and updated epidemiology of restenosis are discussed, alongside the main mechanisms underlying the pathophysiology of this event. Then, we summarize the clinical presentation of restenosis, emphasizing the importance of glycemic control in diabetic patients. Indeed, in diabetic patients who underwent revascularization procedures a proper glycemic control remains imperative.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.